It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

• Main Authors: Ken Akao (Author), Yuko Oya (Author), Takaya Sato (Author), Aki Ikeda (Author), Tomoya Horiguchi (Author), Yasuhiro Goto (Author), Naozumi Hashimoto (Author), Masashi Kondo (Author), Kazuyoshi Imaizumi (Author)
• Format: Book
• Published: Open Exploration Publishing Inc., 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Despite innovative advances in molecular targeted therapy, treatment strategies using immune checkpoint inhibitors (ICIs) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) have not progressed significantly. Accumulating evidence suggests that ICI chemotherapy is i...